Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
08/10/2017 08/11/2017 08/14/2017 08/15/2017 08/16/2017 Date
16.125(c) 16.375(c) 16(c) 15.625(c) 15.625(c) Last
104 663 52 494 0 76 339 22 120 Volume
-0.77% +1.55% -2.29% -2.34% 0.00% Change
More quotes
Financials ( GBP)
Sales 2017 17,7 M
EBIT 2017 -30,7 M
Net income 2017 -24,2 M
Finance 2017 24,7 M
Yield 2017 -
Sales 2018 23,3 M
EBIT 2018 -31,9 M
Net income 2018 -33,3 M
Finance 2018 10,4 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 3,25x
EV / Sales2018 3,08x
Capitalization 82,3 M
More Financials
Company
Vernalis Plc engages in the research, development, and commercialization of pharmaceutical products under the Tuzistra XR brand.The company was founded by Keith G. McCullagh in 1986 and is headquartered in Winnersh, United Kingdom. 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
08/08 VERNALIS : FDA Issues a Complete Response Letter on CCP 08 NDA
08/08 VERNALIS PLC : FDA Issues Complete Response Letter on CCP-08 NDA
08/07 VERNALIS : hit by fresh U.S. setback for cough and cold drug
08/07 VERNALIS PLC : FDA Issues Complete Response Letter on CCP-08 NDA
07/18 VERNALIS PLC : Year-End Trading Update and Notice of Full Year Results
04/26 VERNALIS : Gets EUR2 Million Milestone Payments From Servier Partnership
04/24 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
04/21 VERNALIS : Cough Cold Treatment Drug Application Suffers Setback
04/21 VERNALIS : *panmure cuts vernalis plc to 'hold' ('buy') - target 65 pence
04/21 VERNALIS : receives a $2 million milestone payment from one of its drug discover..
More news
Sector news : Biotechnology & Medical Research - NEC
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
08/10Vernalis stopped cold: US FDA rejects cough medicine NDA -  
08/10EuroBiotech Report—Galapagos data, Vernalis CRL, Orchard names CEO, Roche off.. 
08/07Vernalis closes down 10+% on LSE following FDA CRL on NDA for CCP-08, follow-..
1
08/07Vernalis plc's hold rating reiterated at Panmure Gordon. GBX 31 PT.  
08/07Vernalis plc's PT cut by Stifel Nicolaus to GBX 21. hold rating.  
More tweets
Qtime:6
News from SeekingAlpha
08/11 SNIPPET ROUNDUP : A Small Success For Galapagos And A Big One For Karius
04/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017
04/21 FDA rejects Vernalis' marketing application cough/cold med CCP-07
02/21 Vernalis reports 1H results
2016 Vernalis reports FY16 results
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,52  GBP
Spread / Average Target 231%
EPS Revisions
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Pascal Borderies Senior Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-54.04%106
INCYTE CORPORATION26.03%25 995
QUINTILES IMS HOLDINGS INC18.33%19 819
LONZA GROUP37.66%17 539
CELLTRION, INC.--.--%11 245
ALKERMES PLC-7.12%7 929